HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target
Immix Biopharma Analyst Ratings
H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $7
Immix Biopharma Analyst Ratings
Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential
Buy Rating for Immix Biopharma Backed by Promising N-GENIUS Platform and Strong NXC-201 Sales Potential
Immix Biopharma Analyst Ratings
Roth MKM Reiterates Buy on Immix Biopharma, Maintains $14 Price Target
Immix Biopharma Analyst Ratings
Roth MKM Keeps Their Buy Rating on Immix Biopharma, Inc. (IMMX)
Immix Biopharma Analyst Ratings
Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14